Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
1 finding from 1 review
Kidney failure progression: doubling of SCr (mg/dL) · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
1 finding from 1 review
Kidney failure progression: eGFR (mL/min/1.73m²) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Major cardiovascular event Physicians · Adults with chronic kidney disease not requiring dialysis
Statin therapy leads to lower major cardiovascular events (MACE) compared with placebo or standard of care (high certainty).
1 finding from 1 review
Death · Adults with chronic kidney disease not requiring dialysis
Statin therapy leads to lower death compared with placebo or standard of care (high certainty).
1 finding from 1 review
Rhabdomyolysis · Adults with chronic kidney disease not requiring dialysis
It is very uncertain whether statin therapy changes rhabdomyolysis compared with placebo or standard of care (very low certainty).
1 finding from 1 review
Myocardial infarction · Adults with chronic kidney disease not requiring dialysis
Statin therapy probably leads to lower myocardial infarction compared with placebo or standard of care (moderate certainty).
1 finding from 1 review
Stroke · Adults with chronic kidney disease not requiring dialysis
Statin therapy showed no clear difference in stroke compared with placebo or standard of care (moderate certainty).
1 finding from 1 review
Kidney failure · Adults with chronic kidney disease not requiring dialysis
Statin therapy showed no clear difference in kidney failure compared with placebo or standard of care (moderate certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · Adults with chronic kidney disease not requiring dialysis
Statin therapy showed no clear difference in hospitalisation due to heart failure compared with placebo or standard of care (low certainty).
1 finding from 1 review
ADHD symptoms – improvement – medium term · Children and adolescents with ADHD
Summary of findings table ‐ PUFA may leads to higher ADHD symptoms – improvement – medium term compared with placebo (low certainty).
1 finding from 1 review
ADHD symptoms · Children and adolescents with ADHD
1 finding from 1 review
ADHD symptoms – inattention, parent‐rated – medium term · Children and adolescents with ADHD
1 finding from 1 review
ADHD symptoms – hyperactivity/impulsivity, parent‐rated – medium term · Children and adolescents with ADHD
1 finding from 1 review
Side effects – overall · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in side effects – overall compared with placebo (moderate certainty).
1 finding from 1 review
Loss to · Children and adolescents with ADHD
Summary of findings table ‐ PUFA showed no clear difference in loss to compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in symptoms in infants · GORD in infants
1 finding from 1 review